PCOS Is a Metabolic Condition, Not Just a Reproductive One
When most women first hear the words polycystic ovary syndrome, the conversation centers on irregular periods, acne, unwanted hair growth, and fertility. Those matter, but they are only part of the story. For many women, PCOS is the earliest visible signal that the body is struggling with insulin — years, sometimes decades, before a fasting glucose ever drifts upward.
Understanding PCOS as a metabolic condition changes how we manage it. It is not something you age out of after menopause. The hormonal symptoms may quiet down, but the insulin resistance that drove them often persists and shapes your cardiovascular and diabetes risk for the rest of your life.
A Quick Refresher on the Diagnosis
PCOS is diagnosed using the Rotterdam criteria, which require two of the following three:
- Irregular or absent ovulation
- Clinical or biochemical signs of elevated androgens (hirsutism, acne, male-pattern hair thinning, or elevated testosterone on labs)
- Polycystic ovarian morphology on ultrasound
There is no single blood test that confirms PCOS. The diagnosis is clinical, and other conditions — thyroid disease, prolactin excess, late-onset congenital adrenal hyperplasia — need to be ruled out first. Both the NICHD and ACOG provide helpful patient-facing overviews.
Why Insulin Resistance Sits at the Center
In a majority of women with PCOS — estimates run from 50 to 70 percent — the ovaries are responding to a body that is producing too much insulin. Insulin stimulates the ovaries to make more testosterone, which in turn disrupts ovulation and drives the androgenic features. That is why treatments that lower insulin often improve the whole picture.
This same insulin resistance does not stay contained to the ovaries. Over the long term, it significantly raises the risk of:
- Type 2 diabetes — up to four times the general population risk
- Prediabetes and impaired fasting glucose
- Nonalcoholic fatty liver disease (NAFLD)
- High cholesterol and dyslipidemia
- Hypertension and cardiovascular disease
- Endometrial cancer, due to chronic unopposed estrogen from anovulation
The NICHD summarizes these long-term risks clearly, and current guidelines reflect them.
What Screening Should Look Like
If you have PCOS, your primary care plan should include more than a yearly pelvic exam. I recommend:
- Hemoglobin A1C or oral glucose tolerance test every one to three years, starting at diagnosis. The OGTT is more sensitive — A1C alone can miss early insulin resistance in this population.
- Lipid panel at diagnosis and periodically thereafter
- Blood pressure at every visit
- BMI and waist circumference, which track metabolic risk better than weight alone
- Liver enzymes to screen for NAFLD, especially with abdominal adiposity
- Endometrial surveillance if cycles are chronically absent or very irregular
Our piece on prediabetes and what you can do now is a useful companion read — most of it applies directly.
Lifestyle Is Foundational, Not Optional
For women who carry extra weight, losing even 5 to 10 percent of body weight can be transformative. Cycles regularize, androgens fall, fertility often returns, and the metabolic trajectory bends in the right direction. That is not because weight loss is the cure — it is because reducing visceral fat improves insulin sensitivity at the cellular level.
Practical levers:
- A lower-glycemic, Mediterranean-style eating pattern
- Regular strength training plus aerobic activity — muscle is insulin-sensitive tissue
- Consistent sleep; short or disrupted sleep worsens insulin resistance in hours, not weeks
- Learning how postprandial glucose behaves in your body — our guide on blood sugar spikes walks through the basics
Where Medication Fits In
Metformin
Metformin remains the first-line pharmacologic treatment for insulin resistance in PCOS. It improves ovulation, modestly lowers androgens, supports weight stability, and — most importantly — reduces progression to type 2 diabetes. It is inexpensive, well studied, and generally well tolerated once the gut adjusts.
GLP-1 Receptor Agonists
The newer GLP-1 agonists, including semaglutide, have changed the conversation considerably. For women with PCOS and obesity or established prediabetes, these medications produce meaningful weight loss, improve insulin sensitivity, and lower cardiovascular risk. Evidence specific to PCOS is growing quickly. They are not a replacement for lifestyle change, but for the right patient they can be the tool that makes lifestyle change finally stick.
Other Considerations
Combined oral contraceptives remain useful for cycle regulation, androgen control, and endometrial protection. Spironolactone can help with hirsutism and acne. These address symptoms — they do not address the underlying metabolic disease, which is why the medications above matter so much.
PCOS After Forty and Through Menopause
Many of the women I see with polycystic ovary syndrome were diagnosed in their twenties, managed with birth control, and then quietly dropped from follow-up once fertility was no longer the question. The forties are when the metabolic side of the condition starts to matter most.
The cycles settle down; the risk does not
As ovarian reserve declines, periods often become more regular in the years before menopause, and hirsutism may ease. That can feel like the PCOS is gone. The insulin resistance is not, and the years around perimenopause add their own weight gain, cholesterol shift, and blood pressure rise on top of it. Our perimenopause guide walks through that overlap, which is why I keep the A1C and lipid schedule going right through the transition.
Sleep apnea and fatty liver are common companions
Women with PCOS have a substantially higher rate of obstructive sleep apnea than weight alone would predict, and untreated apnea worsens insulin resistance. Loud snoring, morning headaches, or daytime sleepiness earn a sleep study. Fatty liver disease is the other frequent finding, often first noticed as mildly elevated liver enzymes on routine labs; our fatty liver article explains what happens next. Both are treatable, and both respond to the same weight and insulin measures that help the PCOS itself.
Protecting the uterus when cycles are rare
Months without a period mean the uterine lining is growing without the shedding that progesterone would normally trigger, which over years raises endometrial cancer risk. Fewer than roughly four periods a year is the pattern that prompts either a progestin course or an ultrasound of the lining, and any bleeding after menopause is evaluated promptly. Our endocrine team manages the metabolic side alongside your gynecologist. MedlinePlus and the Endocrine Society patient page are good overviews to share with family members who are also affected.
The Decades-Long View
PCOS management is not a single appointment; it is a relationship. A good plan in your twenties looks different from one in your forties, which looks different again as you approach menopause. What stays constant is the need for regular metabolic screening, cardiovascular risk assessment, and honest conversations about what is working and what is not.
If you have PCOS — or suspect you do — schedule a visit. We will look at the whole picture, not just the hormones, and map out a long-term plan that protects your heart, your blood sugar, and your quality of life for decades to come.
